These glycoproteins are the targets for statins, which are HMGCR inhibitors, to reduce cholesterol levels in patients with hyperlipidemia who are at high risk for cardiovascular events or to reduce future cardiovascular events in patients with established cardiovascular disease [5,6]. Here, HMGCR is linked to cardiovascular disorder.